

STATE OF NEVADA



PERRY FAIGIN
NIKKI HAAG
MARCEL F. SCHAERER
Deputy Directors

J. DAVID WUEST
Executive Secretary

DEPARTMENT OF BUSINESS AND INDUSTRY
OFFICE OF NEVADA BOARDS, COMMISSIONS AND COUNCILS STANDARDS
STATE OF NEVADA BOARD OF PHARMACY

Date Posted: July 1, 2026

THIRD AMENDED AGENDA

◆ PUBLIC NOTICE ◆

The Nevada State Board of Pharmacy will conduct a meeting beginning Wednesday, July 15, 2026, at 9:00 am. The meeting will continue Thursday, July 16, 2026, at 9:00 am if necessary or until the Board concludes its business. Pursuant to NRS 241.023(1)(c) the meeting is being conducted by means of remote technology. The public may attend the meeting via live stream remotely or at the following location:

Hilton Garden Inn
7830 S Las Vegas Blvd
Las Vegas, NV

Via Videoconference at Zoom: <https://zoom.us/j/5886256671>

or

Via Teleconference at 1 (669) 900-6833
Meeting ID: 588 625 6671

Please Note:

In regulating the practice of pharmacy, the Nevada State Board of Pharmacy has a duty to carry out and enforce the provisions of Nevada law to protect the health, safety, and welfare of the public.

Please note that items on this agenda may be taken out of order, two or more agenda items may be combined for consideration, and/or items may be removed from the agenda or delayed for discussion at any time.

The Board may convene in closed session pursuant to NRS 241.030 to consider the character, alleged misconduct, professional competence or physical or mental health of any person named on this agenda.

The Board will take public comment on any matters within their jurisdiction, control, or advisory power. Public comments may be limited to three minutes per person. Public comment may also be submitted to the Board at teambc@pharmacy.nv.gov.

The Board may refuse to consider public comment related to a contested case pursuant to NRS 233B.126 until the Board has rendered a decision in the contested case.

1. Call to Order and Roll Call – Establishment of Quorum
2. Public Comment: No action may be taken upon a matter raised under this item of the agenda until the matter itself has been specifically included on a future agenda as an item. (NRS 241.020)

◆ CONSENT AGENDA ◆

The Consent Agenda contains matters of routine acceptance. The Board Members may approve the consent agenda items as written or, at their discretion, may address individual items for discussion or change.

3. Approval of the June 3-4, 2026, Board Meeting Minutes (**FOR POSSIBLE ACTION**)
4. 4.1 Applications for Out-of-State Medical, Devices, Equipment and Gases License (NAC 639.6944) – Non-Appearance (**FOR POSSIBLE ACTION**)
 - A. Medline Industries LP – Grayslake, IL
 - B. Medline Industries LP – Perryville, MD
 - C. Medline Industries LP – Salt Lake City, UT
 - D. Medline Industries LP – Southaven, MS
 - E. Medline Industries LP – Temecula, CA
 - F. Medline Industries LP – Tolleson, AZ
 - G. Medline Industries LP – Tracy, CA
 - H. National Diabetes Care LLC – Orange City, FL
 - I. Noctrix Health Inc – Pleasanton, CA
 - J. Optum Distribution Center LLC – Marietta, GA
 - K. Remedy Medical Supply Inc – Westlake Village, CA
 - L. Velo Rehab LLC – Wellsville, UT
 - M. Venture OneSource LLC – Missoula, MT
 - N. Warrior Service Company LLC – Boise, ID
- 4.2 Applications for Out-of-State Wholesaler License (NRS 639.233) – Non-appearance (**FOR POSSIBLE ACTION**)

Background Check Not Required by Law.

4.2.1 Publicly Traded (NAC 639.593(6)(a))

- O. Axogen Corporation – Alachua, FL
- P. Medline Industries LP – Hammond, LA
- Q. Medline Industries LP – Katy, TX
- R. Medline Industries LP – Mebane, NC
- S. Medline Industries LP – Moreno Valley, CA
- T. Medline Industries LP – St. Peters, MO
- U. Medline Industries LP – Temecula, CA

4.2.2 Publicly Traded and VAWD-Accredited (NAC 639.593(6)(a) and (c))

- V. Medline Industries LP – Auburndale, FL
- W. Medline Industries LP – Grayslake, IL
- X. Medline Industries LP – Jeffersonville, IN
- Y. Medline Industries LP – Lacey, WA
- Z. Medline Industries LP – McDonough, GA
- AA. Medline Industries LP – Montgomery, NY
- BB. Medline Industries LP – Perryville, MD
- CC. Medline Industries LP – Rialto, CA
- DD. Medline Industries LP – Salt Lake City, UT
- EE. Medline Industries LP – Southaven, MS
- FF. Medline Industries LP – Tolleson, AZ
- GG. Medline Industries LP – Tracy, CA
- HH. Medline Industries LP – Uxbridge, MA
- II. Medline Industries LP – Wilmer, TX

4.2.3 Publicly Traded and Manufacturer (NAC 639.593(6)(a) and (d))

- JJ. Excelsior Medical LLC – Tinton Falls, NJ
- KK. Inhibrx Biosciences Inc – La Jolla, CA
- LL. Medline Industries LP – Glen Falls, NY
- MM. Medline Industries LP – Mundelein, IL
- NN. Milestone Pharmaceuticals USA – Charlotte, NC
- OO. Summit Therapeutics Inc – Princeton, NJ

4.2.4 Publicly Traded, VAWD-Accredited, and Manufacturer (NAC 639.593(6)(a), (c), and (d))

4.2.5 VAWD-Accredited (NAC 639.593(6)(c))

PP. Western Wellness Solutions LLC – Columbus, OH

4.2.6 Manufacturer (NAC 639.593(6)(d))

QQ. AdvaGen Pharma Ltd – East Winsor, NJ

RR. Almaject Inc – Morristown, NJ

SS. Alvogen Inc – Morristown, NJ

TT. Amicus Therapeutics US LLC – Philadelphia, PA

UU. Amivas (US) LLC – Frederick, MD

VV. Amtouch Dental Supply – Valencia, CA

WW. Atland Pharmaceuticals LLC – Atlanta, GA

XX. Avedro, A Glaukos Company – Burlington, MA

YY. Cepheid – Lodi, CA

ZZ. Galt Pharmaceuticals LLC – Atlanta, GA

AAA. Pharvaris Pharmaceuticals Inc – Lexington, MA

BBB. Praxis Packaging Solutions, Grand Rapids, MI

CCC. Priovent Therapeutics Inc – Boston, MA

DDD. UroNova Pharmaceuticals Inc – Windsor, CO

4.2.7 VAWD-Accredited and Manufacturer (NAC 639.593(6)(c) and (d))

4.2.8 Distributor for Single Manufacturer (NAC 639.593(6)(e))

4.2.9 Background checks completed in compliance with NRS 639.500.

EEE. DHL Supply Chain (USA) – Clayton, IN

FFF. DHL Supply Chain (USA) – China Gove, NC

GGG. National Drug Wholesale LLC – Santa Clara, CA

HHH. Perfero Pharma Inc – Rodeland, NJ

III. Pine Plains Pharmacy – Pine Plains, NY

JJJ. Premium Health Services Inc – Columbia, MD

4.3 Application for Nevada Pharmacy License (NRS 639.230) – Non-Appearance (**FOR POSSIBLE ACTION**)

KKK. Carson Tahoe Pharmacy – Carson City, NV

LLL. ER at Inspirada – Henderson, NV

MMM. Vita Pharmacy 2 – Las Vegas, NV

4.4 Application for Out-of-State Compounding Pharmacy License (NRS 639.2328) –

Non-Appearance **(FOR POSSIBLE ACTION)**

- NNN. Cedar Pharmacy LLC- Twin Falls, ID
- OOO. East Coast Compounding and Pharmacy LLC – Jacksonville, FL
- PPP. Evolucionaria Pharma LLC – Stafford, TX
- QQQ. Mountain Care Pharmacy – Boise, ID
- RRR. Mythic Rx Inc – Millcreek, UT
- SSS. Pharmko Inc – Lawrence, NY
- TTT. Sandrx – Wylie, TX
- UUU. US Compounding Factory LLC – Hicksville, NY

4.5 Application for Out-of-State Pharmacy License (NRS 639.2328) – Non-Appearance **(FOR POSSIBLE ACTION)**

- VVV. BioPlus Specialty Infusion AL LLC – Dothan, AL
- WWW. Fidelis Specialty Pharmacy – Arcadia, CA
- XXX. H&H Pharmacy – Brentwood, TN
- YYY. Kroger Pharmacy #011 – Jeffersonville, IN
- ZZZ. Lifeline CMO Pharmacy – Ellicott City, MD
- AAAA. Nufactor Inc – Ronkonkoma, CA
- BBBB. Pharmacy Express – Paterson, NJ

4.6 Application for Ambulatory Surgery Center License (NAC 639.4992) – Non-Appearance **(FOR POSSIBLE ACTION)**

- CCCC. Ear, Nose & Throat Surgery Center LLC – Las Vegas, NV
- DDDD. Summit Surgical Center LLC – Las Vegas, NV

4.7 Request to Engage in The Practice of Pharmacy at a Site Other Than a Licensed Pharmacy – Non-Appearance **(FOR POSSIBLE ACTION)**

- EEEE. Jimmy Kimber – Henderson, NV
- FFFF. Krystal Riccio – Henderson, NV
- GGGG. Zachary Rosko – Las Vegas, NV

4.8 Recommended Denial of Registration/Licensure Due to Material Omissions on Application – Non-Appearance **(FOR POSSIBLE ACTION)**

4.9 Application for Nevada Warehouse (NAC 639.622) – Non-Appearance **(FOR POSSIBLE ACTION)**

◆ REGULAR AGENDA ◆

5. Disciplinary hearings pursuant to NRS 639.247. **(FOR POSSIBLE ACTION)**
 - A. Matthew Apel (24-044-PD-A-S)
 - B. Hisbay Ali (24-444-CS-S)
 - C. Marika Lenee Kerr (25-146-CS-S)
 - D. David McCleve (26-125-CS-S)
 - E. Irene Benliro (25-266-PD-A-S)
 - F. Joanne Mosqueda (25-266-PD-B-S)
 - G. Ibrahim Fakhouri (25-274-CS-A-S)
 - H. Nirav Gandhi (25-274-CS-B-S)
 - I. Darrell Linders (25-289-CS-O)
 - J. Total Infusion Care, Inc (25-501-PH-S)
 - K. Mohammad Pourteymaur (25-501-RPH-S)
 - L. Summerlin Hospital Medical Center Pharmacy (25-209-PH-S)
 - M. Aurelia Hurtada-Sadowski (25-209-RPH-S)

6. Appeal hearing pursuant to NRS 639.2895(2) **(FOR POSSIBLE ACTION)**
 - A. Carolina Molina (25-146-S)
 - B (1). Motion to Dismiss for Kent Holtorf (25-289-C-O)
 - B (2). Kent Holtorf (25-289-C-O)

7. Rehearing of Decision of the Board (NRS 639.252) **(FOR POSSIBLE ACTION)**
 - A. Darlene Hess (24-460-PTT-S)

8. Applications for Nevada Medical, Devices, Equipment and Gases License (NAC 639.6944) – Appearance **(FOR POSSIBLE ACTION)**
 - A. Vegas Medical Supplies Corp. – Las Vegas, NV
 - B. Vitality Medical Supplies – Las Vegas, NV

9. Applications for Nevada Pharmacy License (NRS 639.230) – Appearance **(FOR POSSIBLE ACTION)**
 - A. Dignity Health Rehabilitation Hospital – Henderson, NV
 - B. Genuine Care Pharmacy – Las Vegas, NV
 - C. Health Works Pharmacy – North Las Vegas, NV
 - D. Kaiser Permanente Ion Pharmacy – Sparks, NV
 - E. Patient Care Pharmacy – Las Vegas, NV
 - F. Premier Rx Pharmacy – Las Vegas, NV

10. Application for Out-of-State Outsourcing Facility (NRS 639.100) – Appearance **(FOR POSSIBLE ACTION)**

- A. Bravado Pharmaceuticals LLC – Lutz, FL
- 11. Application for Nevada Outsourcing Facility (NRS 639.100) – Appearance (**FOR POSSIBLE ACTION**)
 - A. Bespoke Pharmaceuticals, LLC – Las Vegas, NV
- 12. Application for Nevada Wholesaler License (NRS 639.233) – Appearance – (**FOR POSSIBLE ACTION**)
 - A. Biowound Solutions – Las Vegas, NV – Background Check Not Required by Law
 - B. Crossroads Courier Inc – Las Vegas, NV – Background Check completed in compliance with NRS 639.500
 - C. DHL Supply Chain – Reno, NV – Background Check Not Required by Law
 - D. E Surgical LLC – Sparks, NV – Background Check Not Required by Law
 - E. J Med Supplies NV Inc – Las Vegas, NV - Background Check completed in compliance with NRS 639.500

◆ WORKSHOP ◆

Thursday, July 16, 2026 – 9:00 am

- 13. Notice of Proposed Regulation Workshop Pursuant to NRS 233B.061(2) (**FOR POSSIBLE ACTION**):
 - A. Amendment to Nevada Administrative Code (NAC) 639. The proposed amendments establishes record keeping requirements of controlled substances by a pharmacy and other matters properly relating thereto.
 - B. Amendment to Nevada Administrative Code (NAC) 639. The proposed amendment requires packaging used to ship prescriptions to contain a device which monitors the temperature of the prescription and alerts the patient if the prescription is exposed to temperatures outside the temperature range listed in the manufacturer’s package insert.
- 14. General Counsel Report. Note: The Board may exclude the public for a report on potential or existing litigation pursuant to NRS 241.015(3)(b)(2).
- 15. Executive Secretary Report:
 - A. Financial Report
 - B. Issuance of Temporary Licenses and Registrations
 - C. Change of Address Business List

- D. Meetings with Other Health Care Regulatory Boards
- E. Licensing Activities Report
- F. Citations & Fines issued pursuant to NRS 632.2895
- G. Legislative update

16. Date and Location of Next Scheduled Board Meeting:

September 2-3, 2026 – Reno, NV

17. Public Comment: No action may be taken upon a matter raised under this item of the agenda until the matter itself has been specifically included on a future agenda as an item. (NRS 241.020)

18. Adjournment

Note: We are pleased to make reasonable accommodations for members of the public who are disabled and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the Nevada State Board of Pharmacy, 985 Damonte Ranch Parkway, Suite 206, Reno, NV, 89521, or call Darlene Nases at (775) 850-1440, as soon as possible.

Supporting materials or additional information regarding the meeting may be obtained from Darlene Nases at (775) 850-1440, email teambc@pharmacy.nv.gov or 985 Damonte Ranch Parkway, Suite 206, Reno, Nevada, 89521.

Continuing Education credit of 4 hours, including 1 hour of law, will be given per day of in-person Board meeting attendance pursuant to NAC 639.330(1)(b)(2). You are required to attend the board meeting for a full day to receive CE credit including the law credit.

This notice has been posted at www.notice.nv.gov and www.bop.nv.gov pursuant to NRS 241.020 (4).

**WORKSHOP -
AGENDA ITEM# 13A**

**PROPOSED REGULATION OF THE STATE
BOARD OF PHARMACY**

Workshop – July 16, 2026

EXPLANATION – Matter in *italics* is new; matter in brackets ~~omitted material~~ is material to be omitted, and language in *green text* indicates prior Board-approved amendments that are in the process of being codified.

AUTHORITY: § 1, NRS 639.070

A REGULATION relating to pharmacy; establishing record keeping requirements of controlled substances by a pharmacy; and providing other matters properly relating thereto.

Section 1. Chapter 639 of NAC is hereby amended by adding thereto a new section to read as follows:

- 1. In addition to any other requirements for keeping records, a pharmacy shall maintain the following records on paper or in a computer system used by the pharmacy:*
 - a. A copy of the order placed on an order form approved by the Drug Enforcement Administration (DEA) or a copy of the electronic order through the Controlled Substance Ordering System (CSOS), properly dated and initialed, copies of each unaccepted or defective order form, and any attached statements or other documents.*
 - i. If the copy of the electronic order through CSOS is maintained in a computer system used by the pharmacy, then an electronic initial is acceptable.*
 - b. A copy of the order submitted to the pharmacy's supplier for dangerous drugs and scheduled III through IV controlled substances, properly dated and initialed, copies of each unaccepted or defective order form, and any attached statements or other documents.*
 - i. If the copy of the order is maintained in a computer system used by the pharmacy, then an electronic initial is acceptable.*
 - c. Suppliers' invoices of controlled substances and dangerous drugs.*

Informational

Notification of significant loss to the DEA ([Diversion Control Division | Theft/Loss Reporting, \(DEA-DC-33R1\)\(EO-DEA157R1\) Reporting Theft and Loss During Civil Unrest \(Final\).pdf](#)):

1. **Initial Notification:** Notify the local DEA Field Division Office in writing within **one business day** of discovering the loss or theft.
2. **File DEA Form 106:** electronically within **45 days** after discovery, providing detailed information about the incident and any investigation findings.

**WORKSHOP -
AGENDA ITEM# 13B**

Proposed Regulation of the Nevada State Board of Pharmacy

Workshop

July 16th, 2026

Explanation – Language in *blue italics* is new; language in *red text* [~~omitted material~~] is language to be omitted, and language in *green text* indicates prior Board-approved amendments that are in the process of being codified.

AUTHORITY: §1, NRS 639.070

A REGULATION Amendment to Nevada Administrative Code (NAC) 639. The proposed amendment requires packaging used to ship prescriptions to contain a device which monitors the temperature of the prescription and alerts the patient if the prescription is exposed to temperatures outside the temperature range listed in the manufacturer’s package insert.

Section 1. NAC 639.

- a. A pharmacy that ships a prescription to a patient must use packaging that is reasonably designed to protect the prescription from conditions of temperature, light and humidity during transit in accordance with the requirements of the manufacturer, the United States Pharmacopeia - National Formulary as adopted by reference in paragraph (c) of subsection 1 of NAC 639.670, the pharmacy’s master compound formulation record, or any stability studies performed by the pharmacy. This may include, without limitation, use of temperature tags, time temperature strips, insulated packaging, gel ice packs, or a combination of these as necessary.*
- b. The pharmacy shall notify the patient or patient's agent when the prescription is shipped.*
- c. At the request of the patient or agent, the pharmacy must include a device in the shipping container which monitors the temperature of the prescription and alerts the patient if the prescription is exposed to temperatures outside the temperature range listed in section 1(a).*
- d. The pharmacy shall provide a method by which a patient or patient's agent can notify the pharmacy as to any irregularity in the shipment of the patient's prescription, to include but not be limited to:*
 - (1) timeliness of delivery;*
 - (2) condition of the prescription upon receipt; and*
 - (3) failure to receive the proper prescription drug.*
- e. If a pharmacist determines a prescription drug was compromised during delivery, the pharmacy shall promptly replace the drug.*

Supporting Documentation:

NAC 639.426 Requirements for approval of application. (NRS 639.070, 639.0725, 639.23288)

1. *A licensed pharmacy may practice as an Internet pharmacy only if the pharmacy is certified by the Board pursuant to this section. To be certified by the Board pursuant to this section, a pharmacy must apply to the Board for certification on an application provided by the Board.*

2. *The Board will grant an application for certification as an Internet pharmacy pursuant to this section if:*

(a) The pharmacy is certified by the Verified Internet Pharmacy Practice Sites program of the National Association of Boards of Pharmacy; or

(b) The Board determines that the pharmacy satisfies the requirements of subsection 3.

3. *The Board will grant an application for certification pursuant to paragraph (b) of subsection 2 if the Board determines that the pharmacy:*

(a) Is licensed to practice pharmacy in each state in which the pharmacy will practice pharmacy;

(b) Maintains and enforces policies and procedures which ensure that:

(1) The pharmacy is able to establish the authenticity of a prescription which the pharmacy receives;

(2) The pharmacy will not fill any prescription which has been previously filled by another pharmacy, and if the pharmacy fills any prescription, that prescription will not also be filled by another pharmacy;

(3) The identity of the patient and the prescribing practitioner is verified to be authentic;

(4) A prescription is filled in compliance with all applicable federal and state laws;

(5) A patient or the caregiver of the patient may make a complaint to the pharmacy regarding the prescription of the patient, and if such a complaint is made, the complaint will be investigated thoroughly, the results of the investigation will be communicated to the patient or caregiver and, if the investigation reveals that the operations of the pharmacy resulted in an error in the processing or filling of the prescription, appropriate remedial action will be taken by the pharmacy;

(6) The pharmacy will communicate to a patient or a prescribing practitioner any delay that might jeopardize or alter the drug therapy of the patient with respect to delivering the prescribed drug or device; and

(7) The pharmacy will communicate to a patient information regarding recalls of drugs and the appropriate means to dispose of expired, damaged or unusable drugs or devices;

(c) Obtains and maintains patient information necessary to facilitate review of drug utilization and counseling of patients pursuant to any applicable statutes;

(d) Provides review of drug utilization and counseling of patients pursuant to the applicable statutes in the state in which the patient resides;

(e) Maintains controls of its computer system, information concerning patients and other such confidential information and documents to prevent unauthorized or unlawful access to all such confidential information and documents;

(f) Complies with applicable federal and state laws regarding:

(1) The dispensing of prescription drugs;

(2) Recordkeeping related to the patients served by the pharmacy, the purchase of prescription drugs, and the sale and dispensing of prescription drugs; and

(3) The sale of over-the-counter products, including, without limitation, any special requirements related to products that have been identified as precursors to the manufacture or compounding of illegal drugs;

(g) Ships prescriptions to a patient using a secure and traceable means; and

(h) Ships prescriptions to a patient using packaging or devices which will ensure that the prescription is maintained within appropriate standards pertaining to temperature, light and humidity as described in the United States Pharmacopeia - National Formulary, as adopted by reference in paragraph (c) of subsection 1 of NAC 639.670.

(Added to NAC by Bd. of Pharmacy by R165-01, eff. 12-17-2001; A by R035-06, 9-18-2008)

Draft